Orlistat is suitable for obese patients aged 12 and above, and medication for special populations should be adjusted according to pregnancy, liver and kidney function, and other conditions. The following is a detailed explanation of the drug's suitability for specific populations and medications, including dosage adjustments and contraindications.

1. Adapt to the population

Orlistat is suitable for obese patients aged 12 and above with a BMI ≥ 30kg/m ² or BMI ≥ 95th percentile of the same age, who require a low calorie diet and exercise.

Teenagers under 18 years old should strictly monitor their growth and development indicators to ensure compliance with treatment indications and exclude secondary obesity factors.

2. Medication for special populations

(1) Pregnancy period

Animal studies have shown that orlistat can cause fetal malformations and is contraindicated for pregnant women. Women of childbearing age should take reliable contraceptive measures during medication.

(2) Lactation period

There is currently no data on the entry of orlistat into breast milk, but it is recommended that lactating women avoid or stop breastfeeding as it may affect the absorption of fat soluble vitamins.

(3) Liver dysfunction

Patients with mild to moderate liver dysfunction do not need to adjust the dosage. Patients with severe liver disease should use with caution as it may worsen fat absorption disorders.

(4) Renal insufficiency

Normal use for patients with mild to moderate renal insufficiency. Patients with end-stage renal disease should be cautious as it may increase the risk of oxalate nephropathy.

(5) Elderly patients

The usage is the same for patients over 65 years old as for young patients, but closer monitoring of nutritional status and adverse reactions is required.

(6) Pediatric patients

The standard dosage is available for adolescents aged 12-17, but the safety and efficacy for children under 12 years old have not yet been established.